指南与共识肝病

多学会德尔菲共识声明:脂肪性肝病新命名

A multisociety Delphi consensus statement on new fatty liver disease nomenclature.
指南 / 共识 · J Hepatol · 2023-06-24

由三个大型泛国家肝脏学会主导改良德尔菲法,来自56个国家的236名专家参与4轮在线调查和2次混合会议,共识定义为超多数(67%)投票。74%受访者认为现行命名缺陷足以考虑改名,「非酒精性」和「脂肪性」分别被61%和66%受访者认为有污名化。以「脂肪性肝病」为总称,以「代谢功能障碍相关脂肪性肝病(MASLD)」替代NAFLD,并新增MetALD等类别。

要点

  • 以「脂肪性肝病」为总称,涵盖各种病因的脂肪变性。
  • 以MASLD替代NAFLD,定义需包含5项心血管代谢危险因素中至少1项。
  • 新增MetALD类别描述合并较多饮酒量的MASLD患者。

核心结论

  • 新命名和诊断标准获得广泛支持且无污名化,可提高疾病认识和患者识别。

研究设计与样本

  • 由三个大型泛国家肝脏学会主导的改良德尔菲法共识,来自56个国家的236名专家参与4轮在线调查和2次混合会议,共识定义为超多数(67%)投票。
  • 由命名过程之外的独立专家委员会对缩写及其诊断标准做出最终推荐。

主要发现

  • 4轮调查的应答率分别为87%、83%、83%和78%。
  • 74%受访者认为现行命名缺陷足以考虑改名。
  • 「非酒精性」和「脂肪性」分别被61%和66%受访者认为有污名化。
  • 选择「脂肪性肝病」作为涵盖各种脂肪变性病因的总称。
  • 认为「脂肪性肝炎」是应保留的重要病理生理概念。

关键数值与推荐

  • 选择代谢功能障碍相关脂肪性肝病(MASLD)替代NAFLD。
  • 共识将定义改为包含5项心血管代谢危险因素中至少1项。
  • 无代谢指标且无已知病因者被认定为隐源性脂肪性肝病。
  • 新增代谢和酒精相关/关联肝病(MetALD)类别,描述每周饮酒量较大(女性140-350克/周、男性210-420克/周)的MASLD患者。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The principal limitations of the terms NAFLD and NASH are the reliance on exclusionary confounder terms and the use of potentially stigmatising language. This study set out to determine if content experts and patient advocates were in favour of a change in nomenclature and/or definition. A modified Delphi process was led by three large pan-national liver associations. The consensus was defined a priori as a supermajority (67%) vote. An independent committee of experts external to the nomenclature process made the final recommendation on the acronym and its diagnostic criteria. A total of 236 panellists from 56 countries participated in 4 online surveys and 2 hybrid meetings. Response rates across the 4 survey rounds were 87%, 83%, 83%, and 78%, respectively. Seventy-four percent of respondents felt that the current nomenclature was sufficiently flawed to consider a name change. The terms "nonalcoholic" and "fatty" were felt to be stigmatising by 61% and 66% of respondents, respectively. Steatotic liver disease was chosen as an overarching term to encompass the various aetiologies of steatosis. The term steatohepatitis was felt to be an important pathophysiological concept that should be retained. The name chosen to replace NAFLD was metabolic dysfunction-associated steatotic liver disease (MASLD). There was consensus to change the definition to include the presence of at least 1 of 5 cardiometabolic risk factors. Those with no metabolic parameters and no known cause were deemed to have cryptogenic steatotic liver disease. A new category, outside pure metabolic dysfunction-associated steatotic liver disease, termed metabolic and alcohol related/associated liver disease (MetALD), was selected to describe those with metabolic dysfunction-associated steatotic liver disease, who consume greater amounts of alcohol per week (140-350 g/wk and 210-420 g/wk for females and males, respectively). The new nomenclature and diagnostic criteria are widely supported and non-stigmatising, and can improve awareness and patient identification.

来源:J Hepatol,查看原文。版权归原作者所有。

引用

  1. Rinella ME, Lazarus JV, Ratziu V, et al. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. J Hepatol. 2023. PMID: 37364790. doi:10.1016/j.jhep.2023.06.003

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。